Program Product Updates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Program product updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Program Product Updates Today - Breaking & Trending Today

Eiger BioPharmaceuticals : Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Global Phase 3 D-LIVR study enrollment completion planned in 2021
Peginterferon Lambda for HDV
Global Phase 3 LIMT-2 study initiation planned in 2021
Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies
U.S. commercial launch in January 2021
EMA decision expected in 2H21
Lambda for COVID-19
Lancet Respiratory Medicine (Feld et al, 2021)
Considering strategic options to advance program
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Positive Phase 2 PREVENT study published in
JCEM (Craig et al, 2021)
Corporate
Pro-forma cash, cash equivalents and investments of $176.2M, including $128.8M as of December 31, 2020 plus $47.4M from net PRV sale proceeds received in January 2021, expected to fund planned operations through Q4 2023
Fourth Quarter and Full Year 2020 Financial Results ....

Progeroid Laminopathies , David Cory , Drug Administration , Program Product Updates , Company Annual Report On Form , Prnewswire Eiger Biopharmaceuticals Inc , European Medicines Agency , Eiger Biopharmaceuticals Inc , Access Program , Hepatitis Delta Virus , Processing Deficient Progeroid , Lancet Respiratory Medicine , Post Bariatric Hypoglycemia , Full Year , Priority Review Voucher , Hutchinson Gilford Progeria Syndrome , Marketing Authorization Application , Managed Access Program , Quarterly Report , Annual Report , Consolidated Statements , Operations Financial , Eiger Biopharmaceuticals , Inc Stock Exchange , Press Release , Of Eigr ,

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021
- Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021
- Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021
News provided by
Share this article
Share this article
PALO ALTO, Calif., March 9, 2021 /PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results for fourth quarter and full year 2020 and provided a business update.
In 2021, we plan to achieve important, value creating milestones in both of our HDV clinical programs, said David Cory, President and CEO of Eiger. We will complete enrollment of the Phase 3 D-LIVR study of Lonafarnib, the first and only ....

Progeroid Laminopathies , David Cory , Drug Administration , Program Product Updates , Company Annual Report On Form , Prnewswire Eiger Biopharmaceuticals Inc , European Medicines Agency , Eiger Biopharmaceuticals Inc , Access Program , Hepatitis Delta Virus , Processing Deficient Progeroid , Lancet Respiratory Medicine , Post Bariatric Hypoglycemia , Full Year , Priority Review Voucher , Hutchinson Gilford Progeria Syndrome , Marketing Authorization Application , Managed Access Program , Quarterly Report , Annual Report , Consolidated Statements , Operations Financial , Eiger Biopharmaceuticals , டேவிட் கோரி , ப்ரோக்ர்யாம் ப்ராடக்ட் புதுப்பிப்புகள் , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் ,